Valuation: Cogstate Limited

Market Cap 569M 397M 354M 330M 300M 565M 38.21B 3.98B 1.55B 19.5B 1.49B 1.46B 62.68B P/E 2027 *
26.5x
P/E 2028 * 21.2x
Enterprise Value 505M 352M 314M 293M 266M 501M 33.9B 3.53B 1.38B 17.3B 1.32B 1.29B 55.61B EV / Sales 2027 *
4.72x
EV / Sales 2028 * 3.98x
Free-Float
56.35%
Yield 2027 *
1.48%
Yield 2028 * 1.75%
1 day+3.31%
1 week+3.31%
Current month+3.31%
1 month+10.90%
3 months+30.00%
6 months+56.00%
Current year+46.25%
1 week 2.34
Extreme 2.34
2.34
1 month 2.26
Extreme 2.265
2.34
Current year 1.26
Extreme 1.26
2.4
1 year 1.26
Extreme 1.26
2.4
3 years 0.55
Extreme 0.553
2.4
5 years 0.55
Extreme 0.553
2.4
10 years 0.14
Extreme 0.14
2.4
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 16/12/1999
Chief Executive Officer - 30/11/2005
Director of Finance/CFO - 31/01/2021
Director TitleAgeSince
Director/Board Member - 28/02/2011
Chairman 67 02/11/2009
Director/Board Member - 19/01/2017
Change 5-day change 1-year change 3-year change Capi.($)
+3.31%+3.31% - - 400M
+4.16%+3.42%+49.37%+94.17% 74.31B
+0.62%-3.77%+20.09%+74.59% 56.95B
+2.44%+0.96%+5.81%+37.44% 48.3B
-0.95%+2.94%+344.62%+722.17% 44.51B
+2.43%-1.80%+28.78%+34.51% 43.8B
+0.71%-1.46%+5.17%+111.90% 41.12B
-0.54%+2.41%+9.31%+58.85% 31.07B
+4.51%+8.22%+37.86%+32.49% 28.97B
+2.36%-1.45%-7.44%-11.12% 24.53B
Average +1.89%-0.15%+54.84%+128.34% 43.73B
Weighted average by Cap. +1.85%-0.46%+58.72%+136.73%

Financials

2027 *2028 *
Net sales 107M 74.54M 66.5M 61.95M 56.38M 106M 7.18B 749M 291M 3.66B 280M 274M 11.78B 123M 85.41M 76.19M 70.98M 64.6M 122M 8.23B 858M 334M 4.2B 321M 314M 13.49B
Net income 21.73M 15.14M 13.51M 12.59M 11.45M 21.57M 1.46B 152M 59.17M 744M 56.85M 55.62M 2.39B 26.88M 18.73M 16.71M 15.57M 14.17M 26.69M 1.8B 188M 73.2M 921M 70.33M 68.81M 2.96B
Net Debt -64.24M -44.77M -39.94M -37.21M -33.86M -63.77M -4.31B -450M -175M -2.2B -168M -164M -7.07B -81.78M -56.99M -50.85M -47.37M -43.11M -81.18M -5.49B -572M -223M -2.8B -214M -209M -9.01B
Logo Cogstate Limited
Cogstate Limited is a neuroscience technology company optimizing brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Its principal activities are the creation, validation, and commercialization of digital brain health assessments; and design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments. Its segments include Clinical Trials, Healthcare, and Administration. In the Clinical Trials segment, the technology and associated services are used to quantify the effect of disease and of drugs, devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical, and biotechnology companies. In the Healthcare segment, the technology and associated services are being developed as a tool for primary care physicians and/or hospitals to assess cognitive decline.
Employees
160
Date Price Change Volume
01/10/26 US$2.340 +3.31% 293
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.340AUD
Average target price
4.312AUD
Spread / Average Target
+29.11%

Quarterly revenue - Rate of surprise